Singapore-based medtech Biorithm has secured $3.5m in a Series A funding round.

Existing investor SEEDS Capital and new investor Adaptive Capital Partners co-led the funding round.

Focused on women’s health, Biorithm is engaged in developing solutions for personalised connected maternity care.

The funding will allow the company to expand into South-East Asia and the US.

Biorithm said it is planning to advance its comprehensive obstetric remote monitoring solution, Femom.

It also plans to complete clinical studies to support a 510(K) premarket submission to the US Food and Drug Administration (FDA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The Femom solution is designed to allow patient monitoring and provide personalised guidance.

By allowing unified integration of predictive analytics, the tool helps clinicians detect early signs of complications.

In addition, the company will use the fresh infusion to conduct more research to demonstrate the effective deployment of remote care.

It is also considering key partnerships with various stakeholders to enhance maternal and baby health through data and tailored care.

Biorithm medical advisory board chairman Julian Robinson said: “Biorithm will enhance care, minimise inconvenience, and reduce cost for patients and improve the efficiency and effectiveness of the clinical health care provider. Above all, it will improve medical outcomes for mothers and their babies.”

Adaptive Capital Partners founder and managing partner Shi Ying said: “Building a system of connected medical care is crucial to help clinicians predict, diagnose, and formulate calculated decisions on early intervention to prevent complications and devise treatments.

“We are excited with our investment into Biorithm as the company is focused on creating measurable and actionable value in maternal health, integrating this system across all touchpoints to ensure safety throughout the pregnancy journey.”